Sherbrooke Park Advisers LLC Day One Biopharmaceuticals, Inc. Transaction History
Sherbrooke Park Advisers LLC
- $313 Billion
- Q4 2024
A detailed history of Sherbrooke Park Advisers LLC transactions in Day One Biopharmaceuticals, Inc. stock. As of the latest transaction made, Sherbrooke Park Advisers LLC holds 14,865 shares of DAWN stock, worth $177,339. This represents 0.06% of its overall portfolio holdings.
Number of Shares
14,865Holding current value
$177,339% of portfolio
0.06%Shares
1 transactions
Others Institutions Holding DAWN
# of Institutions
175Shares Held
77.8MCall Options Held
139KPut Options Held
253K-
Atlas Venture Life Science Advisors, LLC6.43MShares$76.7 Million13.44% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.85MShares$69.8 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.76MShares$68.7 Million1.18% of portfolio
-
Braidwell LP Stamford, CT4.87MShares$58.1 Million3.46% of portfolio
-
Black Rock Inc. New York, NY4.53MShares$54.1 Million0.0% of portfolio
About Day One Biopharmaceuticals, Inc.
- Ticker DAWN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 73,461,104
- Market Cap $876M
- Description
- Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...